AdipoGen Life Sciences


CHF 30.00
In stock
AG-CR1-3592-M0055 mgCHF 30.00
AG-CR1-3592-M02525 mgCHF 65.00
AG-CR1-3592-M100100 mgCHF 170.00
More Information
Product Details
Synonyms 1-OHP; ACT 078; RP 54780; NSC 266046; Diaminocyclohexane oxalatoplatinum
Product Type Chemical


MW 397.3
Merck Index 14: 6912
CAS 61825-94-3
RTECS TP2275850
Purity Chemicals ≥98% (1H-NMR)
Appearance White to off-white powder.
Solubility Soluble in DMSO (20mg/ml)* or water (2mg/ml). Slightly soluble in methanol. Insoluble in ethanol.
Identity Determined by 1H-NMR.
Other Product Data

*Solvent Note: Even though Oxaliplatin is soluble in DMSO, the use of DMSO to dissolve Oxaliplatin in biological studies is not recommended. The DMSO was found to insert itself into the ligand, resulting in loss of activity (see M.D. Hall, et al.; 2014).

Smiles O=C1O[Pt]2(N[C@H]3CCCC[C@@H]3N2)OC1=O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Potent platinum-based antineoplastic agent with wide spectrum anticancer activity [2, 7-9].
  • Anticancer compound. Forms inter- and intrastrand DNA adducts/crosslinks, consequently blocking DNA replication and transcription and inducing cell death [1, 4, 7, 10, 13].
  • Shows antitumor activity in cisplatin resistant cell lines [3, 8].
  • Shows better biochemical, pharmacological and cytotoxic properties than cisplatin (Prod. No. AG-CR1-3590) and carboplatin (Prod. No. AG-CR1-3591) [5, 7, 8].
  • Apoptosis inducer [10, 11].
  • Targets other proteins and enzymes [6].
  • Anticancer activity and antitumor specificity depends on selective uptake through human organic cation transporters 1 (OCT1) and OCT2 [12].
  • Neurotoxic profile depends on organic cation transporter 2 (OCT2) uptake [14].
Product References
  1. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers: L. Pendyala, et al.; Cancer Lett. 97, 177 (1995)
  2. Oxaliplatin: mechanism of action and antineoplastic activity: E. Raymond, et al.; Semin. Oncol. 25, 4 (1998) (Review)
  3. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells: A Nehme, et al.; Br. J. Cancer 79, 1104 (1999)
  4. Oxaliplatin-induced damage of cellular DNA: J.M. Woynarowski, et al.; Mol. Pharmacol. 58, 920 (2000)
  5. What is the "best" platinum: cisplatin, carboplatin, or oxaliplatin? J. Lokich; Cancer Invest. 19, 756 (2001)
  6. Biomolecular targets for platinum antitumor drugs: R.N. Bose; Mini Rev. Med. Chem. 2, 103 (2002)
  7. Cellular and molecular aspects of drugs of the future: oxaliplatin: A.M. Di Francesco, et al.; Cell. Mol. Life Sci. 59, 1914 (2002) (Review)
  8. Cellular and molecular pharmacology of oxaliplatin: E. Raymond, et al.; Mol. Cancer Ther. 1, 227 (2002)
  9. New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA: J. Reedijk; PNAS 100, 3611 (2003)
  10. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells: S. Faivre, et al.; Biochem. Pharmacol. 66, 225 (2003)
  11. Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line: P. Marchetti, et al.; Anticancer Res. 24, 219 (2004)
  12. Organic cation transporters are determinants of oxaliplatin cytotoxicity: S. Zhang, ;et al.; Cancer Res. 66, 8847 (2006)
  13. Inhibition of transcription by platinum antitumor compounds: R.C. Todd & S.J. Lippard; Metallomics 1, 280 (2009) (Review)
  14. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2: J.A. Sprowl, et al.; PNAS 110, 11199 (2013)
  15. Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin and Other Platinum Complexes: M.D. Hall, et al.; Cancer Res. 74, 3913 (2014)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.